MA43753A - Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu - Google Patents
Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbuInfo
- Publication number
- MA43753A MA43753A MA043753A MA43753A MA43753A MA 43753 A MA43753 A MA 43753A MA 043753 A MA043753 A MA 043753A MA 43753 A MA43753 A MA 43753A MA 43753 A MA43753 A MA 43753A
- Authority
- MA
- Morocco
- Prior art keywords
- dbu
- cyano
- inhibitors
- pyrrolidine derivatives
- pyrrolidine
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- QJRYYOWARFCJQZ-UHFFFAOYSA-N pyrrolidine-1-carbonitrile Chemical class N#CN1CCCC1 QJRYYOWARFCJQZ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1605059.3A GB201605059D0 (en) | 2016-03-24 | 2016-03-24 | Novel compounds |
| GBGB1700839.2A GB201700839D0 (en) | 2017-01-18 | 2017-01-18 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43753A true MA43753A (fr) | 2018-11-28 |
Family
ID=58455357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043753A MA43753A (fr) | 2016-03-24 | 2017-03-23 | Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11352339B2 (fr) |
| EP (1) | EP3433246B1 (fr) |
| JP (1) | JP6959252B2 (fr) |
| CN (1) | CN108884068B (fr) |
| MA (1) | MA43753A (fr) |
| WO (1) | WO2017163078A1 (fr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3277677B9 (fr) | 2015-03-30 | 2021-07-14 | Mission Therapeutics Limited | Composés 1-cyano-pyrrolidine utilisés comme inhibiteurs d'usp30 |
| CN107849013B (zh) | 2015-07-14 | 2022-03-29 | 特殊治疗有限公司 | 作为dub抑制剂用于治疗癌症的氰基吡咯烷类 |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| WO2018060689A1 (fr) | 2016-09-27 | 2018-04-05 | Mission Therapeutics Limited | Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| EP3642196B1 (fr) | 2017-06-20 | 2022-08-17 | Mission Therapeutics Limited | Cyanopyrrolidines substituées présentant une activité en tant qu'inhibiteurs de dub |
| IL272838B2 (en) | 2017-10-06 | 2023-09-01 | Forma Therapeutics Inc | Peptidase-specific ubiquitin inhibition 30 |
| GB2571731A (en) * | 2018-03-06 | 2019-09-11 | Mission Therapeutics Ltd | Novel compounds and uses |
| BR112020021921A2 (pt) | 2018-05-17 | 2021-01-26 | Forma Therapeutics, Inc. | compostos bicíclicos fundidos úteis como inibidores de peptidase 30 específica de ubiquitina |
| US11572374B2 (en) | 2018-08-14 | 2023-02-07 | Amgen Inc. | N-cyano-7-azanorbornane derivatives and uses thereof |
| PL3860989T3 (pl) * | 2018-10-05 | 2023-07-10 | Forma Therapeutics, Inc. | Sprzężone piroliny, które działają jako inhibitory proteazy 30 swoistej dla ubikwityny (usp30) |
| WO2020132561A1 (fr) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Dégradation ciblée de protéines |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| AU2020311940A1 (en) | 2019-07-11 | 2022-02-03 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as LRRK2 inhibitors |
| GB201912674D0 (en) * | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| AU2021253617A1 (en) * | 2020-04-08 | 2022-12-01 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as USP30 inhibitors |
| CN115667252A (zh) | 2020-05-28 | 2023-01-31 | 特殊治疗有限公司 | 用于治疗线粒体功能障碍的作为usp30抑制剂的n-(1-氰基-吡咯烷-3-基)-5-(3-(三氟甲基)苯基)噁唑-2-甲酰胺衍生物和对应噁二唑衍生物 |
| AU2021285130A1 (en) | 2020-06-04 | 2023-01-19 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as USP30 inhibitors |
| ES3040433T3 (en) * | 2020-06-08 | 2025-10-30 | Mission Therapeutics Ltd | 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis |
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| WO2023099561A1 (fr) | 2021-12-01 | 2023-06-08 | Mission Therapeutics Limited | N-cyanopyrrolidines substituées ayant une activité en tant qu'inhibiteurs de l'usp30 |
| CN114646700B (zh) * | 2022-03-01 | 2023-10-20 | 浙江国邦药业有限公司 | 一种（s）-吡咯烷-2-甲腈盐酸盐的检测方法 |
| GB202408928D0 (en) | 2024-06-21 | 2024-08-07 | Mission Therapeutics Ltd | Novel compounds |
| GB202411060D0 (en) | 2024-07-29 | 2024-09-11 | Mission Therapeutics Ltd | Novel compounds |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665754A (en) | 1993-09-20 | 1997-09-09 | Glaxo Wellcome Inc. | Substituted pyrrolidines |
| CA2404630A1 (fr) | 2000-04-06 | 2001-10-18 | Merck Frosst Canada & Co. | Inhibiteurs de proteases a cysteine de type cathepsines |
| WO2013064445A1 (fr) | 2011-11-01 | 2013-05-10 | F. Hoffmann-La Roche Ag | Composés d'imidazopyridazine |
| GEP201606597B (en) | 2012-11-02 | 2017-01-10 | Pfizer | Bruton's tyrosine kinase inhibitors |
| GB201309085D0 (en) | 2013-05-20 | 2013-07-03 | Redx Pharma Ltd | Compounds |
| NZ715838A (en) | 2013-07-31 | 2020-05-29 | Merck Patent Gmbh | Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof |
| SI3060550T1 (sl) * | 2013-10-21 | 2019-09-30 | Merck Patent Gmbh | Heteroarilne spojine kot inhibitorji BTK in uporabe le-teh |
| GB201404987D0 (en) | 2014-03-20 | 2014-05-07 | Redx Pharma Ltd | Compounds |
| WO2015157955A1 (fr) * | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Inhibiteurs de tyrosine kinase de bruton (btk) hétérocyclique |
| CN105017256A (zh) | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| WO2016019237A2 (fr) * | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibiteurs de la tyrosine kinase de bruton |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| DK3209656T3 (da) | 2014-10-24 | 2020-07-13 | Bristol Myers Squibb Co | Indolcarboxamidforbindelser, der er anvendelige som kinasehæmmere |
| EP3277677B9 (fr) | 2015-03-30 | 2021-07-14 | Mission Therapeutics Limited | Composés 1-cyano-pyrrolidine utilisés comme inhibiteurs d'usp30 |
| WO2016192074A1 (fr) | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Inhibiteurs de la btk |
| CN107849013B (zh) | 2015-07-14 | 2022-03-29 | 特殊治疗有限公司 | 作为dub抑制剂用于治疗癌症的氰基吡咯烷类 |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| US10570118B2 (en) | 2016-01-13 | 2020-02-25 | Boehringer Ingelheim International Gmbh | Isoquinolones as BTK inhibitors |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| EP3436451B1 (fr) | 2016-03-30 | 2021-09-29 | University Of Virginia Patent Foundation | Promédicaments d'amidoxine inhibiteurs de la sphingosine kinase |
| CN107383013B (zh) | 2016-05-16 | 2020-03-31 | 苏州信诺维医药科技有限公司 | 作为btk抑制剂的吡唑并嘧啶衍生物及其制备方法和药物组合物 |
| WO2017198050A1 (fr) | 2016-05-16 | 2017-11-23 | 浙江予川医药科技有限公司 | Dérivé de 5-aminopyrazole carboxamide en tant qu'inhibiteur de la btk, son procédé de préparation et composition pharmaceutique associée |
| WO2018060689A1 (fr) | 2016-09-27 | 2018-04-05 | Mission Therapeutics Limited | Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
-
2017
- 2017-03-23 MA MA043753A patent/MA43753A/fr unknown
- 2017-03-23 US US16/087,515 patent/US11352339B2/en active Active
- 2017-03-23 WO PCT/GB2017/050830 patent/WO2017163078A1/fr not_active Ceased
- 2017-03-23 CN CN201780018998.XA patent/CN108884068B/zh active Active
- 2017-03-23 EP EP17714540.6A patent/EP3433246B1/fr active Active
- 2017-03-23 JP JP2018549534A patent/JP6959252B2/ja active Active
-
2022
- 2022-02-18 US US17/674,943 patent/US11945797B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108884068B (zh) | 2021-02-26 |
| EP3433246A1 (fr) | 2019-01-30 |
| WO2017163078A1 (fr) | 2017-09-28 |
| US20220177451A1 (en) | 2022-06-09 |
| JP6959252B2 (ja) | 2021-11-02 |
| CN108884068A (zh) | 2018-11-23 |
| US20200331888A1 (en) | 2020-10-22 |
| EP3433246B1 (fr) | 2022-05-04 |
| US11352339B2 (en) | 2022-06-07 |
| US11945797B2 (en) | 2024-04-02 |
| WO2017163078A8 (fr) | 2017-12-28 |
| JP2019513135A (ja) | 2019-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43753A (fr) | Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu | |
| EP3478687A4 (fr) | Dérivés de pyrazolopyrimidine comme inhibiteurs de kinase | |
| MA45591A (fr) | Dérivés de 1,3-dihydroxy-phényle utiles comme immunomodulateurs | |
| CL2018002892A1 (es) | Composiciones de conjugado de ácido nucleico dirigido. | |
| MA41251A (fr) | Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk | |
| PT3687999T (pt) | Derivados de rapamicina | |
| MA45646A (fr) | Derives de benzimidazole comme des modulateurs de ror-gamma | |
| DK3442980T3 (da) | Heterocykliske forbindelser som ret-kinase-hæmmere | |
| LT3371190T (lt) | Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai | |
| DK3356345T3 (da) | Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer | |
| MA41677A (fr) | Composés alpha-cinnamide et compositions comme inhibiteurs de hdac8 | |
| LT3609898T (lt) | Junginiai, naudingi kaip ret inhibitoriai | |
| MA41898A (fr) | Dérivés de quinazolinone bicyclique | |
| EP3397629A4 (fr) | Composés inhibiteurs de métallo-enzymes | |
| MA41977A (fr) | Imidazopyrazinones utilisées comme inhibiteurs de pde1 | |
| IL255310A0 (en) | Thioether compounds as nitrification inhibitors | |
| MA42597A (fr) | 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| EP3457851A4 (fr) | Dérivés de sobétirome | |
| EP3334726A4 (fr) | Compositions de plinabuline | |
| DK3116475T3 (da) | Dopa-decarboxylasehæmmersammensætninger | |
| DK3717488T3 (da) | Substituerede furanopyrimidinforbindelser som pde1-inhibitorer | |
| PT3240767T (pt) | Composições microencapsuladas de inibidor da nitrificação | |
| DK3544981T3 (da) | Benzodiazoliumforbindelser som enac-inhibitorer | |
| MA41803A (fr) | Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques | |
| EP3325526A4 (fr) | Additif de revêtement |